Biotech Holdings Gets Order In China
The Canadian company Biotech Holdings has announced that its subsidiary in China has received a purchase order for 90,000 units of Diab II, Biotech's new product for the treatment of Type II diabetes. The order has a value of C$690,000 ($504,804) and will be delivered in lots of 10,000 packages per month, commencing November.
Biotech said that the purchaser is a pharmaceutical and medical instruments distributor with an extensive marketing network supplying hospitals and retail pharmacies throughout the Shan-Xi province and surrounding areas.
Diab II is approved in China for the treatment of symptoms of impaired glucose tolerance and Type II diabetes. It is estimated that more than 60 million people in China suffer from these conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze